Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 1, 2024
Distillery Therapeutics
Inhibiting transcription factor ETS2 for autoimmune diseases
BioCentury | Jul 26, 2024
Finance
Public Equity Report: Palvella lands on NASDAQ via Pieris merger
Plus: Verastem’s follow-on and Hangzhou Jiuyuan’s IPO plans
BioCentury | Apr 25, 2024
Regulation
FDA’s Ojemda approval marks Day One’s transition to commercial company
No black box warning and a broad label for the pediatric brain cancer therapy
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
BioCentury | Feb 17, 2024
Regulation
With eyes on manufacturing, Iovance’s TIL therapy reaches long-awaited, world-first approval
Therapy will be made at the biotech’s Philadelphia facility and a nearby CDMO, with plans to serve ‘up to several thousand patients annually’
BioCentury | Oct 30, 2023
Regulation
As priority review starts, Day One preps for shift to commercial phase
Five-year-old biotech receives April PDUFA date for pan-RAF inhibitor to treat slow-moving pediatric brain cancer
BioCentury | Jul 28, 2023
Emerging Company Profile
Genuv: multispecific cancer antibodies and neuroprotective small molecules
Seoul-based Genuv is developing a competitor to Roche’s anti-PD-1:IL-2 fusion for solid tumors; advancing a MEK inhibitor for neurodegeneration
BioCentury | May 26, 2023
Discovery & Translation
Excision of CGG repeats in fragile X; plus VLP’s saRNA COVID vaccine and more
BioCentury’s roundup of translational news
BioCentury | Apr 20, 2023
Finance
April 20 Quick Takes: Hasten prepares for acquisitions with $315M raise
Plus: BMS, Tubulis partner and updates from BeiGene, Day One and Enveda
Items per page:
1 - 10 of 419